Blanket Purchase Agreement 36F79720D0213-36E79721A0003
Award Date
10/15/20
Last Date to Order
10/14/25
Federal Agency
National Acquisition Center
Awardee
Servier Pharmaceuticals LLC
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
This Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Servier Pharmaceuticals LLC as a single-award contract with potential value of $12 million. The BPA is for the purchase of the pharmaceutical products Asparlas and Oncaspar, to be delivered over a base year and four option years. The Department of Veterans Affairs provides healthcare services to military veterans. This BPA aims to procure chemotherapy drugs Asparlas and Oncaspar...
The Department of Veterans Affairs (VA) awarded a $19.3 million Federal Supply Schedule (FSS) contract to Servier Pharmaceuticals LLC, a for-profit pharmaceutical company, to provide drugs, pharmaceuticals, and hematology-related products. The FSS-61-IB contract has a period of performance through September 2025 and does not include any set-aside designations. Under this FSS contract, the VA has placed firm-fixed price delivery orders for Servier's specialty oncology medications, such as...
The U.S. Department of Veterans Affairs (VA) awarded a $3.7 million Blanket Purchase Agreement (BPA) to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., a large pharmaceutical manufacturer. The BPA allows VA medical facilities to place firm fixed price call orders for the oncology medications BALVERSA (erdafitinib) and Belzutifan (WELIREG) through July 2024. This streamlined procurement vehicle supports the VA's Veterans Health Administration (VHA) in maintaining a steady...
The U.S. Department of Veterans Affairs (VA) awarded a Blanket Purchase Agreement (BPA) to Takeda Pharmaceuticals America, Inc., a foreign-owned, for-profit manufacturer of pharmaceutical products, under the company's General Services Administration (GSA) Schedule 61-IB for Pharmaceuticals and Drugs. The single-award BPA, valued at over $13 million, is for the supply of the oncology medication ICLUSIG (ponatinib) to various VA Medical Centers and Veterans Integrated Service Networks (VISNs)...
The Department of Veterans Affairs National Acquisition Center has awarded a Blanket Purchase Agreement (BPA) to Helsinn Therapeutics (U.S.), Inc., a for-profit pharmaceutical manufacturer, to provide the drug VALCHLOR. VALCHLOR is used to treat cutaneous T-cell lymphoma. The BPA has a ceiling value of $15,475,951.95 and a period of performance through February 2025. This BPA allows VA medical facilities to efficiently procure VALCHLOR on an as-needed basis to treat veterans with this condition....
The U.S. Department of Veterans Affairs (VA) National Acquisition Center awarded a single-award Blanket Purchase Agreement (BPA) to Sobi, Inc., a foreign-owned, for-profit pharmaceutical company, to provide the drugs TEGSEDI and ORFADIN. The BPA, valued up to $11.75 million, covers the period from October 2021 through September 2025. Sobi, Inc. also holds a multiple award schedule contract with the VA valued at up to $78 million through July 2025 for pharmaceutical products under the Federal...
This Blanket Purchase Agreement (BPA) is a single-award indefinite delivery vehicle (IDV) held by Takeda Pharmaceuticals America, Inc., a subsidiary of the global biopharmaceutical company Takeda Pharmaceutical Company Limited. The BPA, valued at $123.5 million, was awarded by the Department of Veterans Affairs (VA) National Acquisition Center and is set to run through October 2025. The primary purpose of this BPA is to provide the VA with a streamlined procurement mechanism for the specialty...
This Blanket Purchase Agreement (BPA) contract was awarded by the National Acquisition Center, a civilian agency, to Otsuka America Pharmaceutical Inc., a large pharmaceutical manufacturer. The $83,342,090.00 BPA is for the supply of the drug Jynarque (tolvaptan) to the Department of Veterans Affairs (VA) healthcare system. Jynarque is used to treat autosomal dominant polycystic kidney disease and hyponatremia. The BPA was awarded under the Pharmaceuticals and Drugs Federal Supply Schedule...
The U.S. Department of Veterans Affairs (VA) awarded a Blanket Purchase Agreement (BPA) to Advanced Accelerator Applications USA Inc., a foreign-owned, for-profit manufacturer of radiopharmaceuticals. The $7.5 million single-award BPA, issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), covers the delivery of PLUVICTO and LUTATHERA, which are radiopharmaceutical products used for cancer treatment and diagnostic imaging. The VA has awarded Advanced Accelerator...
This Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Amryt Pharmaceuticals Inc., a foreign-owned, for-profit organization, on November 5, 2022. The potential value of the BPA is $1,000,000. No set-aside was used. The BPA is for a single award and permits ordering of Mycapssa, Juxtapid, and Myalept through March 14, 2024. Mycapssa, Juxtapid, and Myalept are pharmaceutical products used to treat certain rare diseases. The Department of...